Navigation Links
Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance
Date:12/10/2009

its partners, Amylin Pharmaceuticals, Inc. and Alkermes, Inc. The companies submitted exenatide once weekly for U.S. regulatory review in the second quarter of 2009. The application was accepted for review by the FDA in the third quarter of 2009. Regulatory action is expected by the end of the first quarter of 2010. European submission is expected to occur by the end of the second quarter of 2010.
  • GLP-Fc - An adaptive, seamless Phase II/III trial, comparing GLP-Fc with both placebo and a positive control, sitagliptin, is proceeding. The company is also finalizing its full Phase III clinical program, known as AWARD, and will begin enrolling patients in the first quarter of 2010. To address the recent FDA guidance regarding mitigation of cardiovascular (CV) risk, a large CV outcomes trial is planned that will likely begin in the first quarter of 2011. Based on the company's current expectations, GLP-Fc could be submitted for U.S. regulatory review as early as late-2012.
  • Teplizumab- The safety and efficacy of teplizumab is currently being studied in both children and adults with newly-diagnosed type 1 diabetes mellitus in two global, pivotal Phase III clinical trials - Protégé and Protégé Encore. The Protégé trial completed enrollment in 2009. Patients who have completed the two-year protocol are currently transitioning into an extension phase evaluating the long-term safety and durability of teplizumab. Protégé Encore, the second global pivotal Phase III clinical trial began enrolling patients in June 2009. Regulatory submission could occur in 2012.
  • Emerging Markets

    The emerging markets business unit will include many of the world's fastest-growing markets, including six of the so-called "pharmerging markets" - China, Russia, Brazil, Mexico, South Korea, and Turkey. Lilly aims to increase its presence in these countries and others where strong growth rate
    '/>"/>

    SOURCE Eli Lilly and Company
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

    Related medicine technology :

    1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
    2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
    3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
    4. Lilly Receives NCQA Design Certification for Depression Care Management Program
    5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
    6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
    7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
    8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
    9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
    10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
    11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/21/2015)... , May 21, 2015  When ... along the side of his neck, he ... took a couple weeks off from weight ... go away.                               A ... 26, was referred to Michel Kliot, ...
    (Date:5/21/2015)... 21, 2015 Research and ... of the "Market Assessment of Respiratory Diagnostics ... to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,This ... imaging diagnostics market in the United ... . The service provides detailed analysis of the ...
    (Date:5/21/2015)... 2015  CryoLife, Inc. (NYSE: CRY ), a ... cardiac and vascular surgery, announced today that its Board ... the second quarter 2015 of $0.03 per share of ... per share will be paid on June 19, 2015 ... 12, 2015.  The ex-dividend date for the quarterly dividend ...
    Breaking Medicine Technology:Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4United States and Europe Respiratory Diagnostics Market Assessment 2015 2CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015 2
    ... Texas, Jan. 3, 2012  MacuCLEAR, Inc., a specialty clinical ... novel solutions for vascular disorders of the eye, ... in funds from current investors.  The funds will ... human efficacy trial for its lead product, MC-1101.  ...
    ... Jan. 3, 2012 Actavis Group, an international ... begun shipping Clobetasol Propionate Shampoo and Clobetasol Propionate ... Shampoo and Clobex ® Topical Lotion.  Due ... Actavis a 180-day marketing exclusivity. Combined ...
    Cached Medicine Technology:MacuCLEAR, Inc. Raises More Than $1M in Financing and Enters into Strategic Pacific Rim Partnership 2Actavis First-To-Market with Generic Equivalents of Clobex® Shampoo and Clobex® Topical Lotion 2
    (Date:5/24/2015)... (PRWEB) May 24, 2015 Medicx ... Millennial Media strategy executive Jay Krihak as its ... looks to ramp up its expertise and leadership ... the Pharmaceutical and Health sectors. , Krihak is ... executive. Most recently, Krihak led sales planning teams ...
    (Date:5/23/2015)... Dr. David Benvenuti, an experienced plastic surgeon who practices ... article to his website that takes an in-depth look ... in the fascinating blog, he has recently had several young ... as “gauging,” the technique involves placing larger and larger gauge ... eventually stretch the holes out to incredible sizes. As the ...
    (Date:5/23/2015)... IL (PRWEB) May 23, 2015 A live ... medical equipment from hospitals, surgery centers and other medical facilities ... be sold including endoscopy, lab, radiology, surgery, anesthesia, exam and ... Wednesday, May 27 and Thursday, May 28 starting at 9:00am ... located at 1400 N. 25th Avenue, Melrose Park, IL 60160. ...
    (Date:5/22/2015)... (PRWEB) May 22, 2015 Pioneer Millworks, ... at the forefront of designing with reclaimed wood, introducing ... in Los Angeles, California. Their newest offerings, Vat 35, ... much-anticipated surface and color to America's largest design event. ... exhibit at each show, anxious to see and feel ...
    (Date:5/22/2015)... Following yesterday’s announcement that Ascenta Health ... health brand Nature’s Way, Marc St-Onge has affirmed his ... Skin is an integral part of the agreement with ... to further develop Ascenta Skin into a leading player ... a breakthrough, anti-aging skincare supplement featuring 6 active ingredients ...
    Breaking Medicine News(10 mins):Health News:Medicx Media Solutions Expands Executive Team 2Health News:Dr. Benvenuti, a Plastic Surgeon in Newport Beach, CA, Posts New Article about Repairing Ear Gauges 2Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 3Health News:Ascenta Skin President Announces Plans to Grow Brand 2
    ... Men,s Health Network & Former Governor Gary Locke ... Oct. 4 Men,s Health Network,American Cancer Society, ... key thought leaders, community organizations, and,policy makers to ... Washington,State. Among presenters will be Former Washington Governor ...
    ... in Disguise, CHICAGO, Oct. 4 Let,s face ... But it,s easy for moms to make Halloween a ... recommend a,treat that won,t haunt anyone,s health: chocolate milk. ... This Official Drink of,Halloween has the chocolaty taste that ...
    ... Bioponic Phytoceuticals,Inc. (Pink Sheets: BPYT) ("Bioponic"), an ... the Complementary Alternative,Medicine (CAM) and nutraceutical markets, announced ... division of National Financial,Communications Corporation, as its investor ... billion in 2005, and approximately 62% of U.S.,adults ...
    ... This Week at Major Medical Meeting Reinforce Need for ... Broader Spectrum Pneumococcal Vaccines -, ... (NYSE: WYE ), comments on studies to be,presented this ... of America (IDSA) concerning PREVNAR(R) (Pneumococcal 7-valent,Conjugate Vaccine [Diphtheria CRM197 ...
    ... BOULDER, Colo., Oct. 4 On October 3, 2007,Encision ... received a letter,from the American Stock Exchange ("AMEX") stating ... with AMEX,s continued listing,standards, and granted the Company an ... continued listing standards. As previously disclosed, on July ...
    ... Oct. 4 More than 35,million children between the ... in,costume this Halloween. Although hours of planning and preparation ... to consider,the importance of security. "Today, most parents check ... sealed wrapper and safe to eat," says Steve,Jones, executive ...
    Cached Medicine News:Health News:Washington Comes Together to Promote Smoking Cessation 2Health News:Chocolate Milk: 'The Official Drink of Halloween' 2Health News:Chocolate Milk: 'The Official Drink of Halloween' 3Health News:Chocolate Milk: 'The Official Drink of Halloween' 4Health News:Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 2Health News:Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations 3Health News:Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease 2Health News:Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease 3Health News:Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease 4Health News:American Stock Exchange Accepts Encision's Plan to Regain Compliance 2Health News:Safety Tips for a Fun and Spooky Halloween 2
    ... P with Tobramycin is the ... formula, with the addition of ... the original formula, surgeons can ... of Simplex™ P Bone Cement, ...
    ... Sir John Charnley and CMW, Inc. ... develop bone cements exclusively for orthopaedic ... 40 years of performance and excellence ... offers one of the first proven ...
    ... 35 years, Palacos Bone Cement ... the gold standard in cemented ... introduction of,the Optivac system in ... provided thousands of physicians the ...
    ... device for ocular precision tonometry. ,The PASCAL ... digital, contact tonometer for ophthalmological applications. The ... intra-ocular pressure (IOP) and of ocular pulse ... a few seconds. It measures pulsatile IOP ...
    Medicine Products: